GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Investments And Advances

Diamyd Medical AB (OSTO:DMYD B) Investments And Advances : kr0.00 Mil (As of Feb. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Investments And Advances?

Diamyd Medical AB's Investments And Advances for the quarter that ended in Feb. 2025 was kr0.00 Mil.


Diamyd Medical AB Investments And Advances Historical Data

The historical data trend for Diamyd Medical AB's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Investments And Advances Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Diamyd Medical AB Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Diamyd Medical AB Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Diamyd Medical AB Business Description

Traded in Other Exchanges
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines